Moreover, COPD is a disease that gets progressively worse3 and therapy might need to be continuously intensified.
Indeed, the quality of life10 worsens when symptoms, such as dyspnoea and cough, get out of control, and the patient might need to be hospitalised. Patients with COPD have unmet therapeutic needs, such as reducing the risk of exacerbations that impair the quality of life, lead to hospitalisation and that may even be life-threatening6, 7, 8, 9. Unmet Therapeutic needs and Chiesi’s commitment. Hence, the triple combination achieves its beneficial effect (including reducing the risk of exacerbations) by concurrently and broadly targeting the two cardinal features of the disease.Īt the same time, the proprietary formulation of extrafine particles (Modulite® technology developed by Chiesi in its Research Centre) ensures that the inhaled drug also effectively reaches and treats the small airways even in the deepest regions of the lungs4, 5. the bronchodilator LAMA (long-acting muscarinic antagonist) glycopyrronium.the bronchodilator LABA (long-acting β2 agonist) formoterol.the anti-inflammatory inhaled corticosteroid (ICS) beclomethasone.The fixed triple combination tested in the TRILOGY and TRINITY studies is the first containing three different active ingredients that improve airflow and fight inflammation: Moreover, the disease presents two different characteristics: an obstructive component that limits airflow especially during expiration, and an inflammatory component, both at the proximal airways and deep lung level3. The study has proven the superiority of the extrafine fixed ICS/LABA/LAMA combination also compared to the LAMA tiotropium, another standard therapy for COPD.ĬOPD affects the respiratory system and particularly the small airways (bronchioles) 3, areas that are usually hard to reach with drugs. Moreover, the results of a second pivotal clinical trial, named TRINITY2, will also be presented on September 5 during the congress. Reduces breathlessness (dyspnoea) and improves patient’s symptom profile.Improves significantly pulmonary function.Reduces the annual incidence of exacerbations, events that are the most threatening for patients and the main cause of hospitalisation, death and high costs for the healthcare system.
#New laba lama combine inhaler series#
The study provided for the first time one year evidence that the extrafine fixed ICS/LABA/LAMA triple combination - developed by Chiesi - is superior to the fixed dose ICS/LABA combined therapy (one of the standard treatments for this condition) regarding a series of clinical efficacy parameters, and demonstrates a high safety profile. London, September 3 2016 – The study (TRILOGY1) published in the special ERS edition of The Lancet - one of the most prestigious international medical journals- is presented on September 3 at the ERS Congress in London.
The results of a second pivotal study, referred to as the TRINITY study, will also be presented during the Congress, providing evidence of the superiority of ICS/LABA/LAMA also against tiotropium.This is another achievement that puts Chiesi and its Research Centres at the cutting edge of the development of innovative therapies for the treatment of COPD.The inhaler has been specifically formulated to deliver extrafine particles efficiently to the lung resulting in marked improvements in patient outcomes.
The results of the study provide convincing support for the first-in-class Triple inhaler for the effective long-term treatment of COPD (Chronic Obstructive Pulmonary Disease).The Lancet publishes the results of Chiesi Farmaceutici TRILOGY study, which shows one year data on the superior efficacy of the first extrafine fixed ICS/LABA/LAMA triple combination for COPD treatment compared with standard therapy.
0 kommentar(er)
